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Two-dimensional (2D) cell cultures growing on plastic do not recapitulate the three dimensional 
(3D) architecture and complexity of human tumors. More representative models are required for 
drug discovery and validation. Here, 2D culture and 3D mono- and stromal co-culture models of 
increasing complexity have been established and cross-comparisons made using three standard cell 
carcinoma lines: MCF7, LNCaP, NCI-H1437. Fluorescence-based growth curves, 3D image analysis, 
immunohistochemistry and treatment responses showed that end points differed according to cell 
type, stromal co-culture and culture format. The adaptable methodologies described here should guide 
the choice of appropriate simple and complex in vitro models.
Despite the increase in the survival rates for many cancers over the past four decades, the discovery of novel effec-
tive drugs has decreased1. Overall, the success rate of novel oncology drugs transitioning in the clinic from phase 
2 to phase 3 is low2. A lack of efficacy was suggested as a main reason for failure3. Since novel drugs are propelled 
to clinical trial based on evidence of efficacy in preclinical models, clearly these models are questionable.
Despite the wealth of data generated, and strong recommendations to upgrade cell culture from 2D to 3D 
models4, few of these more complex model systems have been incorporated into the drug discovery funnel. 
Reproducibility, cost, time to set up, and limited throughput are some of the issues precluding their routine use. 
Importantly, a lack of detailed characterization and cross-comparison of complex models to show added value 
relative to simple 2D models is absent from many published studies. Thus there is still a need for a better under-
standing of these complex models in order to define their utility and limitations so as to then place them in a more 
comprehensive drug discovery cascade.
The PREDECT consortium (www.predect.eu) has assumed the task to compare and better characterize in vitro 
models for oncology research, particularly models that attempt to capture the complexity and heterogeneity of 
human cancers5. Models were set up for three pathologies, breast, prostate, and lung carcinomas. For breast and 
prostate cancer models, MCF7 and LNCaP cell lines were chosen due to their responsiveness to anti-hormone 
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treatment as a standard of care (SOC). The lung adenocarcinoma cell line H1437 is sensitive to the pan-PI3 
kinase/mTOR inhibitor GSK1059615 as the positive control targeted agent selected for the lung pathology6. 
Normal (NF) and cancer-associated fibroblasts (CAF) served to represent the local stroma for prostate and lung 
cancer models7,8. For breast cancer models, no stable breast cancer derived fibroblast cell lines could be obtained, 
and human non-immortalized dermal fibroblasts (HDF) served as the stromal cell compartment. Albeit not 
breast-derived, HDFs are specialized in producing collagen9, which is a predominant ECM component in breast 
cancer10. In previous publications, we have demonstrated that these fibroblasts contribute to a pro-inflammatory 
and pro-angiogenic environment11,12. Indeed, fibroblasts may be defined by their functionality rather than by 
their origin13, and HDFs may functionally be re-programmed by tumor cells to become CAFs14. Thus given their 
ready availability, greater robustness, and suggested functional adequacy, we decided to use HDFs as a surrogate 
for breast-derived CAFs.
Starting from simple 2D monocultures, the complexity was increased stepwise to include stromal cells in 
2D co-cultures, and then growth of the cultures in 3D. 3D cultures were set up either as free-floating sphe-
roids (“floaters”), microencapsulated into inert hydrogels (alginate) and grown in bioreactors (“alginate-BR”), 
or embedded in ECM, all in the presence or absence of stromal cells. ECM embedded cultures were established 
in, (1) Matrigel, a basal membrane extract that induces polarization of normal epithelial cells15, and would thus 
reflect a localized tumor environment, (2) collagen I as an interstitial stroma matrix component, providing an 
invasive growth environment16, and, (3) a 1:1 mix of both. The alginate hydrogel capsules used in the alginate-BR 
models show some similarity to the glycosaminoglycan structure present in the stromal compartment, such as 
the ability to form gels at very low concentrations, attract a cloud of cations, such as Na+ or Ca2+ and incorporate 
high amounts of water into the matrix17. In addition, the inert structure keeps tumor spheroids and stromal cells 
in close proximity, and may be model-tailored by ECM depositions from the embedded cells. In contrast to the 
other models, stirred-tank bioreactors allow for precise control of physicochemical parameters such as pH, O2 
and perfusion rates.
Cell growth was monitored in all models by fluorescence measurements. Also, response to standard of care 
(SOC) hormonal treatment (breast/prostate) or targeted treatment (lung) and chemotherapy (all) was meas-
ured and compared between all models. When stationary growth phase was reached, cultures were analyzed in 
more depth by fluorescence imaging of in situ fixed cultures, as well as immunohistochemistry (IHC) on paraffin 
embedded samples processed into tissue micro-arrays (TMAs). The decision to choose imaging methods that 
leave the cellular organization of the models intact rather than disruptive technologies like genomic or transcrip-
tional profiling, which may provide higher throughput, was taken considering the increasingly recognized role of 
tumor cell heterogeneity in drug response and resistance. The robust protocols established by this collaborative 
effort in combination with the cross-comparisons performed to characterize the models provide a toolbox that 
should help to better incorporate complex models in the drug discovery process.
Materials and Methods
Experimental procedures. Cell lines, passaging, and viral transductions. Cells were passaged according to 
guidelines from ATCC or the cell provider (see Table 1, also for the fluorescence tags).
MCF-7 cells, transduced with the lentiviral vectors PGK-GFP and pCDH-CMV-MCS-EF1-Puro, were kindly 
provided by Professor Cathrin Brisken (EPFL, Switzerland), within the scope of the PREDECT consortium. 
Human dermal fibroblasts (HDF) were transfected with tag-RFP, as described in ref. 12.
Dual function lentiviral vectors pLEX_TRC211/L2N-TurboRFP-c and pLEX_TRC203/CMV-Ren-puro-eGFP 
were generated carrying a huEF1α promoter to drive either a tRFP, or a Renilla luciferase (RLuc)-eGFP fusion 
reporter. The former construct also harbors a firefly luciferase (FLuc) cDNA fused to the neomycin resistance ORF 
under the control of PGK promoter. Lentiviral particles were produced by co-transfecting three plasmids (pack-
aging plasmid psPAX2 (300 ng/well), VSV-G expressing plasmid pMD2.G (30 ng/well) and the vector of interest 
(270 ng/well)) into HEK-293T cells in 6-well tissue culture plates, using lipopolyplex TransIT-LT1 Transfection 
Reagent (Mirus Bio, MIR2305). After 24 hours, complete culture medium (DMEM medium without phenol red, 
supplemented with 10% FBS, 0.04% gentamycin and 1% glutamine) was replaced with medium containing 10% 
BSA. Five days post transfection, the culture supernatant was harvested, aliquoted and frozen. Prostate cancer and 
stromal cells were seeded in 6-well tissue culture plates containing 2 ml culture medium/well. One day after, cells 
were infected with 1 ml viral supernatant in the presence of 8 μ g/ml polybrene (Sigma), centrifuged at 2200 rpm 
for 90 min and incubated at 37 °C, 5% CO2 for 24 h, after which the medium was refreshed. Transduced prostate 
cancer and stromal cells were selected and sorted for uniform fluorescence by flow cytometry (BD FACSAria).
Cell line (source) Type Origin Label
MCF7 (ATCC HTB-22) Epithelial Breast Adenocarcinoma eGFP-FLuc2
HDF (Innoprot P10857) Fibroblast Skin tagRFP
LNCaP (ATCC CRL-1740) Epithelial Prostate Adenocarcinoma tRFP-FLuc
WPMY-1 (ATCC CRL-2854) Myofibroblast Prostate eGFP-RLuc
CAF- PF179T1 (ref. 8) Fibroblast Prostate Adenocarcinoma eGFP-RLuc
NCI-H14372 (ATCC CRL-5872) Epithelial Lung Adenocarcinoma tdTomato
CAF3 Fibroblast Lung Adenocarcinoma eGFP
NF3 Fibroblast Lung eGFP
Table 1.  Cell lines, type, origin, label. 1Referred to as CAF. 2Referred to as H1437. 3As described in M&M.
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NCI-H1437 cells were transduced with a lentiviral construct expressing tomato-RFP (Capital Biosciences, 
Inc.). Lung derived Normal (NF) and Cancer Associated Fibroblasts (CAF) from patient number 4731 were iso-
lated as described previously18. The local ethics committee ‘Ethik-Kommission der Medizinischen Fakultät am 
Universitätsklinikum Tübingen’ approved the study (project number 396/2005V and 159/2011BO2) and a written 
informed consent was obtained from the patient. NF and CAF were immortalized using a virus co-expressing 
hTERT and GFP (Lenti-hTERT-eGFP; Cat No- LG508, BioGenova), as described in ref. 8.
Culture set-up. 2D culture. Cells were seeded in black 96-well clear-bottom microplates (Greiner Bio-One 
#655-088). For cell numbers, medium, and FCS concentration see Table 2. The plates were incubated in a humid-
ified atmosphere with 5% CO2 at 37 °C.
Floater culture. Cells were seeded in 100–200 μ l into low attachment U-bottom 96-well plates (Corning #4520), 
or in 40 μ l of medium into 1.5% (w/v) agarose-coated 384-well plates (Greiner #781090), or 50 μ l of medium into 
low attachment U-bottom 384-well plates (Corning #3830)19. See Table 2 for cell numbers, medium, and FCS 
concentration. The plates were incubated in a humidified atmosphere with 5% CO2 at 37 °C.
3D alginate-embedded stirred-tank Bioreactor cultures (alginate-BR). Tumor cells were inoculated as single cell 
suspensions at a density of 2 × 105 cell/ml into 125 ml stirred tank bioreactors (spinner vessels with straight blade 
paddle impeller, Corning® Life Sciences, BR). Cell aggregation and spheroid size were controlled through manip-
ulation of the stirring rate20. Once compact and spherical shaped spheroids were attained (e.g. 24 h for MCF7 
and 48 h for H1437 cells), the tumor spheroids were microencapsulated in alginate with or without fibroblasts as 
single cells at a 1:1 cell ratio11. The resulting microcapsules, with 500 μ m of diameter, were transferred to 125 ml 
stirred-tank bioreactors and cultured at 80 rpm. Cultures were grown in humidified incubators with 5% CO2 and 
21% O2, with 50% medium exchange every 3–4 days.
3D embedded culture. 3D cultures were embedded in Matrigel (Corning 356231, Lot 3198769, growth factor 
reduced, phenol red, and LDEV-free), Collagen Type I (BD Bioscience 354236, Lot 07484), or a 1:1 mix between 
the two. Collagen was neutralized according to Artym and Matsumoto21. A pH in the range 7.1–7.4 was crucial 
for cells to grow in collagen. Matrigel was used at a final concentration of 4 mg/ml, collagen at 1.5 mg/ml, and the 
mix contained 4 mg/ml Matrigel and 1.5 mg/ml collagen. Cells were suspended in the appropriate matrix (for cell 
numbers, medium, and FCS concentration see Table 2) and seeded in 60 μ l/well into black 96-well plates (Greiner, 
#655090), pre-coated with the respective matrix (30 μ l/well). Matrix without cells served as a background control. 
The matrix was allowed to set for 30 min at 37 °C before adding 90 μ l growth medium into each well. Growth 
medium was carefully removed and replenished every 3 days.
Tumor and stromal cell growth was followed via fluorescence measurements of their respective fluorescent 
protein markers (see Table 1), using a plate reader (see Table S1 for details). Readings from each well were nor-
malized to the reading at day 1 and averaged for each condition. Every condition was run at least in triplicate.
Standard-of-care (SOC) treatment. Drug treatment started when cells entered the exponential growth phase.
In a first experiment, IC50 and IC80 values were determined for Fulvestrant (ICI 182,780), MDV3100, and 
GSK1059615 for all culture formats, using fluorescence as a read-out for growth (drug concentration ranges are 
listed in Table S2).
For alginate-BR cultures, microencapsulated mono and co-cultures were collected from the stirred-tank and 
plated in 96-well plates, with approximately 10 aggregates per well, under orbital agitation. Treatments lasted 4 
days for Docetaxel and GSK1059615 and 10 days for Fulvestrant with medium and drug replenishment every 3–4 
days. Cell viability was determined with CellTiter-Glo® 3D Cell Viability Assay (Promega). For total cell lysis, 
aggregates were incubated with the CellTiter-Glo® reagent for 40 min under strong agitation, pipetted up and 
down quickly 10 times each well, and placed under strong agitation for another 40 min.
In a second experiment, fixed drug concentrations (IC80 for targeted therapy drugs (Fulvestrant (ICI 182,780), 
MDV3100, and GSK1059615) and IC50 for Docetaxel; see Table S2) or an equivalent volume of DMSO as vehicle 
control were selected for growth curves and sample analysis at endpoint.
Tumor and stromal cell growth was followed via fluorescence measurements as above.
2D 3D floater 3D matrix 3D bioreactor
Medium
Tumor 
cells1
Tumor: 
stroma
FBS 
(%) Tumor cells1
Tumor: 
stroma
FBS 
(%)
Tumor 
cells1
Tumor: 
stroma
FBS 
(%) Tumor cells1
Tumor: 
stroma
FBS 
(%)
Breast 6,000 3:1 10 1,000 3:1 10 10,000 10:1 2 20000/ml 1:1 10 DMEM
Prostate2 10,000 10:1 2 1,000 10:1 2 10,000 10:13 2 NA RPMI
Lung 10,000 10:1 10 400/2004 1:1 10 10,000 10:1 2 20000/ml 1:1 10 RPMI
Table 2.  Experimental cell culture conditions. 1Stromal cells were added on top (except for lung in 3D floater 
cultures). 22D and 3D spheroids contained 0.01 nM R1881 (Methyltrienolone). 3Inclusion of more than 1000 
fibroblasts resulted in collagen contraction after less than a week. 4400 tumor cells for mono-cultures, 200 for 
co-cultures.
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Fluorescence in situ microscopy and analysis. At the endpoint, samples of all 3D models were fixed in-situ and imaged 
via fluorescence microscopy. Alginate-BR and embedded 3D cultures were additionally incubated with 10 μ M 
Click-iT® 5-ethynyl-2′ -deoxyuridine (EdU) Alexa Fluor 647 (Life Technologies #C10356) for 2 h and 5 μ g/ml 
Hoechst 33342 (Invitrogen, H3570) for the last 30 min before fixation.
Images were acquired by bright-field and confocal microscopy, depending on the type of analysis. 
Microscopes, lenses, and settings are summarized in Table S1.
For visualization purposes, the z-stacks, with inter-slice z-distances of 10 μ m for embedded samples (except 
for lung) and 1 μ m for bioreactor samples, are shown in maximum intensity z-projections, with all channels 
merged as RGB values. Linear brightness and contrast adjustments of the images were performed using the 
ImageJ open source software22.
Analysis of fluorescent cultures was a multi-step procedure, consisting of: (1) image acquisition as 3D image 
stacks; (2) annotation of culture parameters; (3) image processing & feature acquisition, done by a dedicated 
(semi-)automated 3D image analysis procedure (described in ref. 23), which includes the segmentation of the 
tumor cell spheroids, detection of EdU positive cells within the spheroids, and extraction of features pertaining 
to the size, shape, number of the cancer spheroids; and, (4) data analysis of the features using dedicated R-scripts.
Exceptions to this procedure were necessary for size and shape analysis of alginate-BR and floater cul-
tures, for which 2D images were analyzed using dedicated CellProfiler pipelines. Also, for the quantification 
of EdU-positive cells in alginate-BR cultures, 2D spheroid masks were drawn manually using the RoiManager 
plugin in ImageJ.
Paraformaldehyde fixation and paraffin-embedding. 3D floater, alginate-BR, and collagen or Matrigel/collagen 
mixed embedded cultures were fixed and paraffin-embedded for TMA analysis. For the floater cultures, 100 
spheroids were collected into a falcon tube, washed with PBS and fixed in 5 ml 4% (w/v) paraformaldehyde (PFA, 
Sigma) for 15 min at room temperature (RT). For 3D embedded cultures, the supernatant was carefully removed 
before filling the wells with 4% (w/v) PFA for 20 min at RT. After fixation, samples were washed with PBS and 
stained with Hematoxylin (Mayer’s, 1:1 Hematoxylin: PBS) for 10 sec in order to identify the spheroids in the par-
affin blocks, and then washed three times in PBS. In order to preserve the 3D complex (co)-culture structure dur-
ing the dehydration procedure and consecutive embedding in paraffin, a slightly modified protocol from Pinto 
et al.24 was used: Fixed spheroid pellets were suspended in 30 μ l warm Histogel (Thermo Scientific HG-4000-012). 
For Matrigel/collagen and collagen embedded cultures, three 96-well gel plugs were extracted from the wells and 
sandwiched between two layers of Histogel in 8-well chamber slides (Labtek #155411). Cooled Histogel plugs 
containing the samples were dehydrated in 1 × 50% isopropanol (20 min), 2 × 70% isopropanol (20 min), 2 × 95% 
isopropanol (30 min) and 3 × 100% isopropanol (30 min) at 37 °C. At this point samples could be stored overnight 
in 100% isopropanol at 4 °C before further processing. For good infiltration of paraffin, samples underwent 3 
changes with paraffin wax (each 30 min, at 65 °C) before paraffin embedding.
Alginate-BR samples were collected and fixed in 4% PFA (w/v)/4% sucrose (w/v) for 20 min at RT. As above, 
microencapsulated mono- and co-cultures were pre-stained with Hematoxylin for 10 sec and then washed three 
times with PBS. Cultures were pelleted and embedded in 1% (w/v) high melting temperature agarose (Lonza), 
dehydrated as above, and then embedded in paraffin wax.
TMA preparation from FFPE blocks, staining, and analysis. FFPE blocks are archived centrally at The Institute 
for Molecular Medicine Finland (FIMM) as tissue microarrays (TMA). TMAs were constructed by punching a 
single core with a diameter of 5 mm from the FFPE block using a semi-automatic punching device (MiniCore, 
Mitogen, UK). For FFPE samples with high cell density, a 1 mm core diameter was used. After arraying, TMAs 
were cut in 4 μ m sections on Superfrost objective glasses (O. Kindler Gmbh, Germany) using Microm 355S 
microtome (Thermo Scientific, Waltham, MA). Slides were dried and stored at − 20 °C.
For histopathological examination, paraffin sections (4 μ m) of TMAs were stained with hematoxylin and eosin 
(H&E). IHC was carried out by a standard protocol (details in supplementary methods). Primary antibodies 
used were as follows: Ki67 (Abcam; EPR3610; #92742; 1:4000), cleaved caspase 3 (Cell Signaling Technology; 
#9661; 1:300), estrogen receptor (Abcam; SP1; #16660; 1:100), androgen receptor (Santa Cruz; #13062; 1:750), 
cleaved CK18 (Roche; M30 Cytodeath; #12140322001; 1:200), gamma H2AX (Cell Signaling 2577; 1:200), 
phospho-Histone H3 (Upstate 06–570; 1:1000), cytokeratin 8 (Abcam 53280; 1:2000), Vimentin(Dako M0725; 
1:10000), and E-cadherin (Cell Signaling 3195; 1:1000). Stained TMAs were imaged at 0.33 μ m/pixel resolution 
using a Pannoramic P250 Flash II whole slide scanner (3DHistech, Hungary) equipped with a Plan-Apochromat 
20x (NA 0.8) objective (Zeiss, Germany). Scanned images were uploaded on a Webmicroscope platform, to which 
all PREDECT members had access (http://predect.webmicroscope.net/).
After downloading the images at a scale of 1:4 from the Webmicroscope using SpotFinder, they were analyzed 
using the cell counter plugin from imageJ22.
Statistical analysis. Data sets were analyzed statistically using GraphPad Prism 6, or R scripts for image analysis, 
and tested for normality using the Shapiro-Wilks test. Two-tailed significance tests were performed with p < 0.05 
considered significant. Non-parametric analyses were done with the Mann-Whitney-U-Test, parametric with 
the t-test. For image analysis data, the extension by Welch for unequal variances was used along with a multivar-
iate ANOVA for the comparison of proliferating cells and spheroid size. Multiple groups were compared using 
a one-way ANOVA using the Tukey post-hoc test. Significances are depicted as n.s.: not significant, * p < 0.05, 
* * p < 0.01, * * * p < 0.001.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:28951 | DOI: 10.1038/srep28951
Results
Generation of model platforms. The goal of the PREDECT consortium is to characterize in vitro tumor 
models for target identification and validation by multi-modal cross-comparisons. Models described here include 
2D and floating spheroid cultures (“floaters”), cultures embedded in alginate and grown in stirred-tank bioreac-
tors (“alginate-BR”), as well as extracellular matrix (ECM) embedded cultures, all as mono- and co-cultures with 
stromal fibroblasts (Fig. 1). Cell lines and respective fluorescence tags are listed in Table 1, culture set up in Table 2.
Characterization of model platforms using growth curves. Growth curves, based on fluorescence 
measurements, were established for all the models. The data set for the MCF7 cell line is described in more 
detail as a prototypic model, the results for the LNCaP and H1437 cell lines are summarized as supplementary 
information.
Growth of MCF7 breast cancer cells in 2D cultures was stimulated by the presence of human dermal fibro-
blasts (HDFs) from day six on. Both mono- and co-cultures reached the stationary phase around day ten, but the 
co-cultures attained more than triple the signal of the mono-cultures (Fig. 2A).
Also in floaters, the presence of HDFs stimulated growth by about ten-fold (Fig. 2B). Co-cultures formed 
inside-out spheroids, with the fibroblasts nestled in the spheroid core (Fig. 2H, co-culture images; Fig. S1 for a 
higher magnification of the HDFs in the core of the spheroid).
For the alginate-BR cultures, MCF7 cells were aggregated for 24 hours and then microencapsulated in alginate 
in the presence or absence of HDFs as a single cell suspension, as described in ref. 11. This protocol aims to keep 
the two compartments in close proximity but prevents the formation of inside-out spheroids as observed in the 
floater cultures (Fig. 2I).
The presence of HDFs in the alginate microcapsules lead to a growth stimulation of the tumor cells compared 
to mono-cultures, which reached significance at day 20 (Fig. 2C). Interestingly, co-cultures presented an altered 
morphology and behavior: aggregates formed irregular structures that leaked out of the alginate microcapsules 
(Fig. 2I). This was rarely observed in MCF7 mono-cultures (Fig. 2I). HDFs deposit collagen and other ECM com-
ponents in the alginate capsule, and also secrete pro-inflammatory factors11,25. Increased collagen density26, but 
also paracrine factors, e.g., the cytokine IL627, or growth factors like SDF1 and FGF2, amongst others28, have been 
shown to drive growth and invasion of mammary tumor cells in vitro as well as in mouse models.
MCF7 growth as embedded mono-cultures was strongly matrix-dependent. Matrigel-containing matrices 
supported growth well, as shown by an approx. 30-fold fluorescence increase over time (Fig. 2D,E), whereas the 
tumor cells alone hardly grew in pure collagen (Fig. 2F). Admixing HDFs to the collagen-embedded cultures 
stimulated MCF7 cell growth approx. 6-fold, but fluorescence levels reached at stationary phase were still lower 
than observed in Matrigel-based cultures (Fig. 2D–F, please note different Y-axes). This confirmed observations 
made by Krauss and co-workers who described poor growth of MCF7 mono-cultures in collagen29. MCF7 cul-
tures grown in Matrigel-containing matrices did not benefit from the addition of HDFs (Fig. 2D,E). In all matri-
ces, fibroblasts were observed to closely contact the tumor spheroids (Fig. 2J–L).
To conclude, HDFs stimulated MCF7 growth in all culture formats, except for Matrigel-containing embed-
ded models. Besides structural basement membrane constituents such as laminin, fibronectin, collagen IV etc., 
Matrigel (although growth factor depleted) still contains significant amounts of growth factors that may partially 
obfuscate the effect of the stromal cells30.
Figure 1. The PREDECT 2D/3D model workflow. Three cell lines (MCF7, LNCaP, H1437) belonging to 
three pathologies (breast, prostate, lung) were set up as 2D or 3D models in mono- and co-cultures. Growth 
was monitored via fluorescence, and the cultures imaged in situ by confocal microscopy and analyzed via 
dedicated 2D/3D imaging software, or fixed, paraffin embedded, and processed into TMAs and then analyzed 
via immunohistochemistry (IHC).
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Figure 2. MCF7 breast cancer model characterization using fluorescence-based growth curves. Models 
were set up, and growth of MCF7 tumor cells was measured via GFP fluorescence as described in M&M. 
Stromal cell growth could not be detected. The graphs in the upper panels show growth curves of the mono- 
(green) and co-cultures (blue) grown in (A), 2D, (B), floaters, (C), alginate-BR, (D) Matrigel, (E) Matrigel/
collagen, (F) collagen. Arrows indicate time-points when pictures were taken; significant differences between 
mono- and co-cultures are indicated (* * p < 0.01; * * * p < 0.001). In G-L, fluorescence images corresponding to  
(A–F) are shown. GFP-labeled tumor cells in green, RFP-labeled HDF stromal fibroblasts in red. Scale bars:  
2D, floaters: 100 μ m; alginate-BR, embedded: 50 μ m.
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Response of model platforms to standard of care (SOC) treatment. Targeted compounds, as 
well as a chemotherapeutic SOC treatment, were used to further characterize the models. For estrogen recep-
tor positive breast cancer, Fulvestrant, a full estrogen receptor antagonist31, for prostate cancer, MDV-3100, a 
second-generation androgen receptor inhibitor32, and for lung cancer, GSK1059615, a dual PI3K/mTOR inhib-
itor6 were chosen as targeted treatments. Docetaxel, an anti-mitotic agent, was selected as a chemotherapeutic 
SOC agent for all three pathologies33.
In a first step, IC50 values (IC50s) were established by generating dose-response curves for all models, starting 
treatment once exponential cell growth was observed (see Table S2). In a second step, growth curves were estab-
lished for a single drug concentration per model in order to characterize the effect of the stromal cells on the 
treatments on a cellular level. At the endpoint, when control cultures reached the stationary phase, samples were 
fixed in situ for fluorescence analysis, and formalin-fixed and paraffin embedded for IHC. Targeted drugs, which 
mainly act as cytostatics, were used at an IC80 concentration, whereas Docetaxel, as a cytotoxic agent, was used at 
an IC50 concentration, in order to obtain analyzable samples at the endpoint.
Fulvestrant and Docetaxel affected MCF7 growth in 2D and floater cultures (Fig. 3A,B). The percent inhibition 
was comparable between mono and co-cultures, indicating that HDFs did not provide protection against either of 
the treatments (Fig. S2A/B). It should be noted, however, that Docetaxel and Fulvestrant treated co-cultures had 
higher GFP signals at the endpoint than untreated mono-cultures (Fig. 3A,B).
Docetaxel treatment decreased cell growth in alginate-BR mono- and co-cultures. In stark contrast, 
co-cultures appeared refractory to Fulvestrant treatment until day 16 (Fig. 3C). The latter cultures were indis-
tinguishable from controls, showing a loss of spheroid roundness, and leakage from the alginate microcapsules 
(Fig. 3I). HDFs thus protected MCF7 from Fulvestrant in this culture format (Fig. S2C).
High-energy metabolites released by stromal fibroblasts may induce tumor cell mitochondria activity to pro-
tect from Fulvestrant34. Also, IL-6 secretion has been shown to confer estrogen-independence to MCF7 and other 
estrogen-dependent breast cancer cell lines27. Corroborating the latter, slightly increased levels of IL6 and IL8 
were found in alginate-BR:HDF co-cultures11.
In the matrix-embedded 3D format, Docetaxel and Fulvestrant reduced MCF7 growth in all three matrices 
tested (Fig. 3D–F). Co-cultures provided only a minimal growth benefit in Matrigel, whereas in the Matrigel/
collagen mix and collagen alone, the fibroblast co-cultures protected the tumor cells from treatment (Fig. S2D–F). 
Fibroblasts (in red) remained viable in Fulvestrant-treated co-cultures, whereas chemotherapy eradicated the 
fibroblasts except for when grown in Matrigel (Fig. 3J–L).
Thus HDFs provided not only a growth advantage, as described in the previous section, but also a treat-
ment protection to MCF7 cells, mainly in culture formats with lower levels of nutrients and growth factors (i.e. 
alginate-BR and collagen).
Image analysis of 3D cultures. In order to validate data from the growth curves, and to gain additional 
information on the characteristics of the models, fluorescence images were taken from cultures in situ and sub-
jected to analysis by dedicated image software developed within the consortium23. Size, numbers, and prolif-
eration rates of tumor spheroids in 3D cultures were measured, and correlated with the presence or absence of 
stromal cells, SOC treatment, and culture format. In order to adequately compare treated with untreated cultures, 
images taken at the end of the culture period were analyzed.
Size analysis revealed a characteristic mean and spread for each of the 3D culture formats. Floater cultures 
formed the largest spheroids, with a very small size distribution (0.066 ± 0.004 mm2), and a large gain induced by 
HDF co-cultures (0.16 ± 0.01 mm2). Alginate-BR spheroids were next in size, but showed a wider spread size dis-
tribution (0.10 ± 0.09 mm2 for co-, and 0.037 ± 0.018 mm2 for mono-cultures; Fig. 4A). Matrix-embedded sphe-
roids were clearly smaller than the previous two models, ranging between 0.001–0.003 mm2. Amongst the latter, 
Matrigel supported the largest, and collagen the smallest spheroids, corroborating observations from growth 
curves (Figs 2D–F and 4A). The strong effect of the HDFs on collagen-embedded samples observed in the growth 
curves (Fig. 2F) translated into significantly increased average spheroid areas, although the difference was not as 
striking as observed in the growth curves (Fig. 4A, upper panel). When counting spheroids per area, we found 
that HDFs also affected MCF7 spheroid numbers (Fig. 4A, lower panel). As a result, the total spheroid density is 
higher, as illustrated by the spheroid foreground area fraction in Fig. 4A, lower panel.
Docetaxel and Fulvestrant treatment reduced spheroid sizes of alginate-BR and embedded samples, confirm-
ing the results from fluorescence-based growth curves (Fig. 4B).
Analysis of tumor spheroid size and numbers in situ represents a relatively simple imaging tool that may be 
used to validate and complement simple fluorescence growth analysis. The results from the growth curve analyses 
shown in the previous sections were largely confirmed, validating the approach of using fluorescence as a proxy 
for cell culture growth.
In order to measure effects of the culture formats or SOC treatment on proliferation, alginate-BR and embed-
ded samples were incubated with EdU for 2 hours before fixation to label cells with ongoing DNA synthesis. 
EdU-positive cells were counted per spheroid using an algorithm developed to analyze spheroids in 3D23.
For both alginate-BR, and mixed matrix embedded cultures, a clear treatment-dependent reduction of EdU 
positive nuclei/spheroid was detected (Fig. 4C, compare DMSO (red) with Docetaxel (green) and Fulvestrant 
(blue) treated cultures). The growth-stimulatory effect of admixing HDFs to MCF7 alginate-BR cultures was also 
evident by the increase of EdU-positive nuclei per spheroid and the concomitant boost of the average spheroid 
size (Fig. 4C). In Docetaxel treated samples, the presence of HDFs in MCF7 alginate-BR cultures sustained some 
EdU-positive nuclei, whereas Fulvestrant imposed a complete proliferation block, as suggested by the total lack 
of EdU-positive cells (Fig. 4C). The histogram representation of the above results reveals the large number of 
non-proliferative spheroids in the Fulvestrant treated cultures, which amassed at the baseline in the previous 
scatter plot (Fig. 4E). Fulvestrant thus imposed a relatively slow-acting proliferation block, leaving the spheroids 
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Figure 3. Fluorescence-based growth curves of MCF7 breast cancer models treated with Fulvestrant 
or Docetaxel. Models were set up, and growth of MCF7 tumor cells was measured via GFP fluorescence as 
described in M&M. Stromal cell growth could not be detected. Mono- and co-cultures were treated with 
Fulvestrant or Docetaxel at the concentrations indicated in the fluorescence images (G–L), corresponding 
to IC80 and IC50 values on mono-cultures. Untreated DMSO control curves are indicated with a straight, 
Fulvestrant with a dotted, and Docetaxel with a broken line. Shown are the graphs for mono-cultures (in green) 
or HDF co-cultures (in blue) grown in (A), 2D, (B), floaters, (C), alginate-BR, (D) Matrigel, (E) Matrigel/
collagen, (F) collagen. Arrows indicate start of treatment. Significances are indicated for comparison to DMSO 
treated controls (* ) or monocultures (#) (* p < 0.05; * * p < 0.01; * * * p < 0.001). In (G–L) fluorescence images 
corresponding to (A–F) are shown. GFP-labeled tumor cells in green, RFP-labeled HDF stromal fibroblasts in 
red. Scale bars: 2D and floaters: 100 μ m; alginate-BR, embedded cultures: 50 μ m.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:28951 | DOI: 10.1038/srep28951
mostly intact, whereas Docetaxel killed proliferating cells, resulting in the dissolution of the spheroids. In con-
clusion, both treatments were ultimately active against alginate-BR cultures, but the timing and the effect on the 
cells (cytostatic versus cytotoxic) varied, explaining the differential effect on the growth curves in the bioreactor 
(Fig. 3C).
Analysis of tissue microarrays (TMA). In order to enable the PREDECT consortium to perform a 
side-by-side comparison of models and patient samples, protocols were developed that allowed for fixing, 
Figure 4. In situ image analysis & quantification of 3D models. (A) Scatter plots comparing MCF7 3D 
models by spheroid sizes (upper graph) and numbers (lower graph). Mono- (green dots) and HDF co-culture 
(orange) spheroid areas and numbers derived from maximal intensity projection (MIP) analyses are displayed. 
The size analysis is shown on a logarithmic scale (upper graph). (B) Scatter plots comparing unperturbed 
(red) and Docetaxel (green) or Fulvestrant (blue) treated MCF7 3D cultures via spheroid areas, displayed on a 
logarithmic scale. (C) Quantification of EdU-positive cells in mixed matrix embedded or alginate-BR MCF7 
mono- and HDF co-cultures, treated with Docetaxel (green), fulvestrant (blue) and DMSO control (red). Scatter 
plots of EdU-positive cells per spheroid, with the size of the dots corresponding to the radii of the spheroids, are 
displayed. Negative spheroids are collapsed to the bottom of the plot. (D) the alginate-BR data of (C) is shown 
as a histogram indicating the number of proliferating cells per spheroid. Note the increase of EdU-positive 
spheroids in the HDF co-cultures, and the large number of non-proliferating spheroids in Fulvestrant treated 
cultures. P-values for the comparison between treatment conditions are represented by * -symbols (* p< 0.05;  
* * p< 0.01; * * * p< 0.001), while #-symbols are used for comparison between mono- and co-cultures (#p < 0.05; 
##p < 0.01; ###p < 0.001).
www.nature.com/scientificreports/
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adequate paraffin embedding and staining of the samples in TMAs. The 3D conformation of all model formats 
could be preserved through paraffin-embedding, except for Matrigel, which dissolved during fixation.
The TMAs were stained for a number of markers in order to characterize cell types and cell cycle status (cyto-
keratin 8 (CK8), E-cadherin, estrogen receptor (ER), androgen receptor (AR), Vimentin, Ki67, phospho-Histone 
H3 (pHH3), cleaved cytokeratin 18 (cCK18), gamma H2AX, cleaved caspase 3 (cC3)).
Figure 5. IHC analysis of breast samples. Cultures were fixed, paraffin embedded, and arrayed into TMAs as 
described in Materials and Methods. TMAs were then stained H&E (A–F), as well as for cytokeratin 8 (G–L), 
E-cadherin (M–R), estrogen receptor (S–X), Vimentin (Y–d), Ki67 (e–j), phospho-Histone H3 (k–p), cleaved 
CK18 (q–v), and gamma H2AX (w–B′ ), respectively. Antibodies were detected using a chromogenic DAB assay 
(brown), and samples were counterstained with hematoxylin (blue). Size bars indicate 100 μ m.
www.nature.com/scientificreports/
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H&E staining of the MCF7 models showed the characteristic 3D morphology of the spheroids grown in the 
various culture formats, and revealed differences in their cellular organization, e.g., while floater spheroids were 
rather compact, alginate-BR spheroids displayed small lumens inside (Fig. 5A–F).
CK8 and E-Cadherin as epithelial cell markers were expressed on MCF7 tumor cells in all models (Fig. 5G–R). 
As expected, MCF7 cells expressed ER in the nucleus, although some negative cells were found in the alginate-BR, 
indicating model-induced heterogeneity (Fig. 5S–X). Vimentin-positive fibroblasts were found in all co-culture 
models (indicated by arrows in Fig. 5Z,b,d). As suggested by the fluorescence images, fibroblasts localized to 
the core of the floater cultures, forming inside-out spheroids (Fig. 5Z). Whereas most of the fibroblasts in the 
alginate-BR format were found outside of the spheroids, some had invaded the spheroid core (Fig. 5b). This was 
not observed in embedded cultures (Fig. 5d).
Proliferation was assessed with the general proliferation marker Ki67 and the M-phase-specific marker 
phospho-Histone H3 (Fig. 5e–p). HDF co-cultivation in floater cultures resulted in enhanced proliferation 
compared to mono-cultures (Ki67: 20.9 ± 1.8% vs. 84.8 ± 1.7% * * * p; pHH3: 1.9 ± 0.4% vs. 6.2 ± 1.4% * * p). In 
alginate-BR mono- and co-cultures, approximately 40% or 10% of MCF7 cells were Ki67 and pHH3 positive, 
respectively. No significant differences were observed between mono- and co-cultures, which also held true for 
embedded samples.
Unfortunately, despite employing IC50 or IC80 concentrations rather than maximally efficacious doses for 
Docetaxel and targeted therapies, respectively, treated samples proved very fragile and unstable, and many were 
lost during processing, rendering analysis of treatment effects by TMAs rather impractical.
In conclusion, protocols have been established for in vitro tumor models with increasing complexity. They 
were validated using exemplary cell lines for three pathologies, breast (MCF7), prostate (LNCaP), and lung 
(H1437), following growth and response to SOC treatment via fluorescence-based growth curves. These results 
were corroborated and complemented by in situ 3D image analysis, as well as IHC on TMAs derived from most 
models. Our results demonstrate that in order to more faithfully evaluate the relative contributions of co-cultured 
cells or matrix composition on baseline tumor cell growth rates or responses to drug treatments, a multi-pronged 
approach to the analysis and set-up of complex 3D assays is required. Table S3 provides a comprehensive over-
view on the results of our study, including a rough cost estimate for the set-up of a 96-well plate, spheroid sizes 
obtained in each of the model, fold growth over the course of the experiment, and the effects of the set-up on 
tumor drug sensitivity.
Discussion
The goal of the present study was to establish robust protocols for 2D and 3D culture methods and thoroughly 
characterize them via side-by-side comparisons in order to better understand their applicability for oncology 
drug discovery. The outcome showed that even with a relatively small matrix of tumor and stromal cells in a set of 
different culture formats, the interactions of the individual components result in altered growth characteristics or 
drug responses of the cultures. Thus none of the models presented here will be able to capture all of the aspects of 
tumor biology, but they differ in the degree to which they represent such aspects, and should be used accordingly. 
Along the same line, while some of the observations from this study will be cell type specific, others are more 
related to model set-up, and may therefore be used to draw more generally applicable conclusions. Below, we will 
try to disentangle these observations, and come up with some recommendations that should help to set up com-
plex models in a robust and informative manner for drug discovery and validation purposes.
As shown in the Results section, appropriate analysis of the data from complex 3D models is of utmost impor-
tance. While fluorescence based growth curves are simple and applicable to relatively high throughput experi-
ments, crucial information may be lost by looking at an average response of a whole culture set-up. In the first 
section of the Discussion, the approaches to analyze complex 3D models presented in this study will be compared 
with respect to their cost and benefit.
Since potentially very labor- and time consuming, complex image analyses should strictly focus on key ques-
tions. Here, image analysis was used mainly for two questions, (1) is the approach of using fluorescence intensity 
measurements valid as a proxy for tumor cell growth? and, (2) can we define effects of the culture format and the 
treatments more precisely by molecular imaging, in this case using EdU as a label for replicating cells?
Requirements on image quality (and hence also equipment) depend on the analyses to be performed. Number, 
size, and shape analyses are less demanding than molecular imaging. Sample number and related microscope 
and computing time were the main issues, requiring the availability of an automated imaging system. In the pres-
ent study, spheroid size analyses generally confirmed the data obtained from fluorescence growth curves, thus 
fulfilling its pre-defined task. Discrepancies between fluorescence growth curves and size analyses were found 
when spheroid size wasn’t the main differentiator between treated and untreated cultures (e.g. Fig. 4A, HDF 
effect on collagen-embedded MCF7 cultures), or when size did not correspond to the number of viable cells (e.g. 
Fig. S12A,B). Shape analysis, which may contribute further relevant information, e.g. invasiveness of 3D cul-
tures35, was also performed, but did not provide much additional insight for this study.
Analysis of the proliferation index of the spheroids by quantifying EdU-stained nuclei proved a much more 
difficult task, despite the availability of a ‘2.5D analysis’ workflow that reduced the complexity of real 3D analysis 
to a combination of maximal intensity projection and height mapping23. Image quality had to be adequate: lateral 
and axial resolution as well as inter-slice distance had to be well below cell-radius (estimated 5 μ m), and spheroids 
needed to be physically separated by at least 10 μ m along the axial direction, and non-overlapping in the lateral 
direction. Moreover, spheroids larger than 100 μ m could not be analyzed because of light attenuation. However, 
despite being resource-intense and demanding on image quality, the analyses performed for the present man-
uscript provided relevant information. The pro-proliferative effect of the HDFs on MCF7 could be shown on a 
cellular level, and the anti-proliferative effect of Fulvestrant as opposed to the cell killing mediated by Docetaxel 
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could clearly be distinguished (Fig. 4C,D). Thus, if probes are available to monitor the effect of a given treatment 
by molecular imaging, the investment in molecular image analysis may well be worthwhile.
TMA-based analysis was chosen by the PREDECT consortium as the means of choice for the cross-comparison 
of models, and ultimately patient material, since tissue heterogeneity is preserved, and it represents the gold 
standard for pathologists.
Processing samples for TMAs proved labor intensive, and was not entirely successful, e.g. analysis of treated 
samples was severely hampered by the loss of already treatment-reduced sample material. However, successful 
analyses addressed several open questions, or independently confirmed previous findings. These included the 
presence of stromal cells in lung and breast floaters (Figs 5 and S13), the puzzling apparent lack of an effect of 
Docetaxel on H1437 alginate-BR spheroids (Fig. S12), and the increase of fibroblasts in treated LNCaP models 
(Fig. S11B). Moreover, avenues for further investigations were opened, such as the suggestion of an EMT induc-
tion in LNCaP 3D samples (Fig. S11C). The latter represents a good example for the necessity to preserve sample 
heterogeneity, even in LNCaP mono-cultures. A more in-depth analysis of the results, and their comparison to 
other models and patient samples, remains yet to be done, and will be published in a follow-up manuscript by the 
PREDECT consortium. Thus albeit labor intensive, once samples have been generated and arrayed into TMAs, 
the depth of analysis possible is only restricted by the number of antibodies that work in FFPE material.
The next sections focus on ‘lessons learnt’ from the analysis of the models presented here. As mentioned 
above, some observations appeared model/set-up specific, and are therefore likely to translate to additional cell 
systems or pathologies, whereas others were clearly cell-type-specific, and will need to be established for every 
model. However, also for the latter, some general guidelines that may help to speed up the set-up time for new 
models will be discussed.
Spheroid sizes appeared to be platform rather than pathology-dependent. Spheroid size matters, since only 
when a minimal radius of about 200 μ m is exceeded, spheroids may form apoptotic cores due to hypoxia and 
lacking nutrients36–38. Hypoxia is prevalent in human tumors due to lacking, or disorganized vasculature, and 
numerous approaches have been explored to target hypoxia as a treatment paradigm39. Another aspect of sphe-
roid size is drug penetration. Spheroid cultures have been shown to be resistant to cytotoxic agents due to a lack 
of appropriate drug exposure40–42. For some drugs, this could be directly correlated to spheroid sizes43. Ineffective 
drug penetration into solid tumors indeed has been suggested to lead to drug resistance44. Not surprisingly, also 
gene transcription is strongly affected by spheroid sizes (Boghaert et al., manuscript in preparation). Larger 
LNCaP floaters had apoptotic cores (Fig. S11A), and the cultures showed some resistance to MDV-3100, albeit 
not Docetaxel (Fig. S6).
Differences between Matrigel and Collagen embedded cultures have been observed consistently across the 
models. Overall, cultures containing Matrigel tended to grow better, or be less sensitive to growth inhibition, or 
both. (1) MCF7 cells grew well in Matrigel or mixed matrix, but collagen was a poor substrate; (2) the maximal 
Model Plus Minus Applications
2D
mono
- simple, cheap
- reproducible
- fully automatable-H/MTS amenable
- limited predictivity for drug effects in 
patients
- extremely high matrix stiffness
- (TD) tumor cell signaling
- (TD, R) genetic alterations in tumor cells
co - stroma derived growth benefit/drug resistance - space restriction - (TD, R) tumor-stroma interactions
floater
mono
- 3D architecture
- drug penetration through tumor cell 
layers
- hypoxic core (if large enough)
- fully automatable - MTS amenable
- not all tumor cells form spheroids
- requires assay 
development (uniformity, growth…)
- complex assay analysis
- no extracellular matrix interaction
- (TD, R) 3D architecture
- (TD, R) tumor hypoxia
- (R) drug penetration
co - often form inside-out spheroids- very few stromal cells survive
BR
mono
- control of physico-chemical parameters
- large batches of uniformly encapsulated 
spheroids 
- tumor-specific ECM deposition
- re-plating of spheroids for multi-
parameter testing 
- initial investment for set-up
- (TD, R) tumor-specific ECM deposition
co
- preformation prevents inside-out 
spheroids 
- stromal cells provide GF and ECM 
  - (TD, R) stromal GF, ECM deposition
matrigel
mono
- provides rich basement membrane-like 
matrix
- widely used, well published
- contains variable amounts of GF
- considerable batch-to-batch variations
- melts upon fixation in formalin
- (TD, R) extracellular matrix
- (TD) invasion
- (R) matrix-derived GF
co - fibroblasts do not differentiate - co-culture effects may be masked by 
matrix GF
collagen
mono
- provides interstitial stroma matrix 
environment
- simulates invasive environment
- some epithelial tumor cells may not 
grow
co - natural environment for fibroblasts - no/low confounding GF present - activated fibroblasts contract matrix - (TD, R) stromal GF
Table 3.  Overview of platforms with strengths/weaknesses & suggested applications. Italic: apply for 
methods below as well (tumor-stroma effects only for co-culture models); Abbreviations: H/MTS: high/medium 
throughput screening; GF: growth factor(s); ECM: extracellular matrix; (TD): find targets/test drugs addressing; 
(R): resistance mechanisms related to.
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growth inhibitory effect of MDV-3100 on LNCaP cultures in Matrigel containing matrices was reduced to about 
30–40% (compared to > 60% in collagen; data not shown); (3) the IC50 values for Docetaxel and GSK1059615 
treated H1437 cultures were approx. six fold higher in pure Matrigel than in collagen (Table S2). Growth factors 
present in the Matrigel preparation (even if growth-factor reduced) may provide cues for growth, survival, and 
invasion of the tumor cells, although the differential composition of the extracellular matrices may also play an 
important role. Various Matrigel lots may behave differently, which is why performance tests are imperative, and 
all groups working on this manuscript used the same Matrigel batch. Attempts to use synthetic Matrigel replace-
ment matrices have not proven satisfactory yet in our hands (data not shown), but if successful, such matrices 
might provide the means to disentangle matrix from growth factor-dependent effects.
Growth factors and/or cues from basement membrane components within Matrigel also appeared to override 
aspects of co-cultures. Breast MCF7 cultures responded with a growth boost when incubated with HDFs in all but 
Matrigel-containing culture formats (Fig. 2). Also, the protective effect of HDFs was much more pronounced in 
collagen than in Matrigel-containing culture formats (Fig. S5). Similarly, CAFs increased the IC50 of GSK1059615 
on H1437 in collagen by > 30-fold. This was less pronounced in mixed matrix cultures, and not detected in 
Matrigel (Table S2). Thus, this would be consistent with a certain Matrigel-induced override of the communi-
cation between co-cultured stromal cells and tumor cells. Interestingly, however, the effect of co-cultures may 
even surpass the Matrigel effect, as was the case for GSK1059615 treated H1437 cells in co-cultures with CAFs 
(Table S2). But then, MCF7 cells in collagen failed to reach the fold fluorescence increase as in Matrigel, even in 
the presence of HDFs.
How important is the correct source of stromal fibroblasts? In prostate and lung, immortalized tissue-specific 
CAFs were available to the consortium, but not for the breast models, despite efforts to cultivate and immortalize 
primary fibroblasts from patients. HDFs were used as a substitute, but a sample of CAFs was purchased from a 
commercial vendor, and compared to HDFs in the spheroid model. A comparable growth stimulation was found 
for both types of fibroblasts (Fig. S14A), suggesting functional adequacy of the HDFs, as also observed by other 
groups14. In the lung H1437 alginate-BR model, HDFs provided a growth stimulation of the tumor cells, but not 
CAFs or NFs (Fig. S5B). Thus, although it may have to be confirmed on a case-to-case basis, HDFs appear to rep-
resent a viable substitute for tumor-specific CAFs, eliminating the need for difficult-to-obtain CAFs from cancer 
patients, which may prevent most non-specialized labs from their routine use.
No one single tumor:stroma ratio could be identified that would be optimal for all models. For MCF7 cultures, 
a strong growth-promoting effect by HDFs was observed in most culture formats, across ratios of 1:1 to 10:1. In 
the lung, a 10:1 ratio did not provide a growth benefit in 2D, whereas a 1:1 ratio did (Fig. S4A vs S5A), suggesting 
a slightly less flexible system. However, such an initial tumor:stroma ratio is not expected to remain constant over 
the course of an experiment. For example, in the MCF7/HDF alginate-BR co-culture model, the original 1:1 ratio 
shifted in the course of the experiment to approximately 6:1, mainly due to a lack of stromal cell proliferation 
(data not shown). In the floater cultures, the original 3:1 ratio likely increased even more dramatically over time, 
since at the end of the experiment only very few stromal cells were left at the center of the tumor (Fig. 5). Only in 
treated prostate tumor LNCaP/WPMY-1 co-culture models was a decrease of the tumor:stroma ratio over time 
observed (Fig. S6). In an experiment to check the optimal tumor:stroma ratio for collagen embedded MCF7 
cultures, a range of ratios between 1:1 to 20:1 was tested. Only at a ratio of 20:1 dropped the growth rate down to 
near mono-culture levels (Fig. S14B). Thus, even though human pathology should be used as a rough guideline 
for a given pathology, a range of tumor:stroma ratios between 1:1 to 10:1 appears to be a good starting point for 
a co-culture set-up.
In conclusion, there is no one-fits-all model, the choice of the model depends entirely on the question that 
needs to be answered (see Table 3). If the genetic make-up of a tumor cell that responds to a given treatment needs 
to be found, then a screen of a large number of molecularly characterized cell lines in 2D may be sufficient45. 
However, if a given target relies on cell-cell, or cell-ECM interactions, more complex models will be required. This 
is also true if not only sensitivity, but also resistance to a given new treatment should be investigated. Thus, for 
studies, which consider drug penetration issues, or target hypoxia (e.g. ref. 19), floater spheroid cultures appear 
best suited since appropriate spheroid sizes are reached. Alternatively, pre-grown larger spheroids embedded 
in ECM, hypoxia chambers, or the alginate-BR system in low O2 conditions may be applied for such studies. 
When looking at the effect of the ECM, Matrigel embedded cultures are most widely used. However, results may 
be confounded by the presence of growth factors and their concentration heterogeneity in different batches. 
Therefore, collagen or, once shown to be a real alternative, synthetic matrices in the presence or absence of stro-
mal co-cultures may be a better choice46,47. Also alginate-BR cultures, which provide a biologically inert struc-
ture that may be functionalized by the encapsulated cells, appear to be a viable alternative. Tumor:stroma ratios 
between 1:1 and 10:1 were found to be functional, with lower ratios to be used in systems where fibroblast growth 
is expected to be minimal, resulting in decreased, more physiologically relevant ratios in ‘mature’ cultures. This 
should also be considered when looking at compounds that specifically target the interface between tumor and 
stromal cells48. If looking at compounds that target stroma for resistance mechanisms, a small matrix of tumor 
and stroma cells should be tested in order to best cover tumor heterogeneity, as has already been performed in 
2D49. Also, not only stromal cells but also macrophages and other constituents of the immune system, as well as 
components of the vasculature play important roles in treatment resistance and should be included in in vitro 
assays that may ultimately get closer to model patient tumors50–52.
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